Florida / New York / No Carolina
Ph: 561.316.3330

Highly Accurate AI Diagnostic Tool Can Predict Cancer Cell Behavior, Developed by Hebrew University Researchers

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...


  • The ability to collect and analyze new types of data brings up new possibilities for the field, with the potential to revolutionize clinical treatment and diagnosis through the development of new tools.

An innovative, new method that highly accurately predicts cancer cell behavior could advance cancer diagnosis and treatment has been developed by researchers at the Hebrew University of Jerusalem.

The new diagnostic tool discussed in Science Advances uses a novel method combining nano informatics and machine learning (ML) to classify cells based on the uptake of cell particles with diverse sizes. It could also enhance personalized medicine by facilitating rapid and accurate testing of cancer cell behaviors from patient biopsies, leading to the development of new clinical tests to monitor disease progression and treatment effectiveness.

Current diagnostic methods like imaging scans and tissue biopsies are invasive, expensive and time-consuming, leading to delays in treatment and potential misdiagnoses. These approaches also may not capture the dynamic nature of cancer progression offering limited insights into the disease’s behavior at the cellular level. As a result, there is an urgent need for more effective and non-invasive diagnostic tools.

Doctoral student Yoel Goldstein and Prof. Ofra Benny from the Hebrew University School of Pharmacy in the Faculty of Medicine led the study, in collaboration with Prof. Tommy Kaplan, Head of the Department of Computational Biology at the School of Engineering and Computer Science.

The initial phase involved exposing cancer cells to particles of various sizes, each identified by a unique color. Subsequently, the precise quantity of particles consumed by each cell. Machine learning algorithms then analyzed these uptake patterns to predict critical cell behaviors, such as drug sensitivity and metastatic potential.

“Our method is novel in its ability to distinguish between cancer cells that appear identical, but behave differently at a biological level,” Goldstein says. “This precision is achieved through algorithmic analysis of how micro and nanoparticles are absorbed by cells. The ability to collect and analyze new types of data brings up new possibilities for the field, with the potential to revolutionize clinical treatment and diagnosis through the development of new tools.”

The research has paved the way for new types of clinical tests that could significantly impact patient care,” says Prof. Benny. “This discovery allows us to potentially use cells from patient biopsies to quickly predict disease progression or chemotherapy resistance and could also lead to innovative blood tests that assess the efficacy of targeted immunotherapy treatments.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

VitaFlow Liberty ™ Granted EU CE-MDR Mark

Jeff Lindstrom, President of CardioFlow, stated, "The certification of VitaFlow Liberty by the CE regulatory body under MDR, is a testament to CardioFlow's world-class R&D, quality, and clinical capabilities. This recognition will expedite the global clinical adoption of the VitaFlowTM series along with other innovative products, advancing CardioFlow's globalization strategy. This achievement also positions us to make a more substantial contributions to developments in the field of heart valve interventions, ultimately benefiting patients across the globe."

Inspira Receives 1st Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S.

Inspira reports the first units are expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA™ ART100.

Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility

The purchase order includes deliveries for both the 10mL and 50mL specialty copolymer prefillable syringes that will be manufactured at the West Columbia site being acquired from Nephron. This assurance of supply is expected to support the planned expansion of the 503b operations at the Nephron site. The new copolymer syringe technology reflects the pharmaceutical and healthcare industry’s trend toward transitioning injectable drug therapies into innovative polymer prefillable syringes and away from the older glass and standard plastic syringes reports Sharps Technology.

By using this website you agree to accept Medical Device News Magazine Privacy Policy